HedgeChatter

  • Home /
  • Tag Archives

AGIO

Agios Pharmaceuticals Announces Pricing of Public Offering of Common Stock

[Business Wire] – Agios Pharmaceuticals, Inc. today announced the pricing of its underwritten public offering of 2,000,000 shares of its common stock at a public offering price of $44.00 per share, before underwriting discounts. moreView todays social media effects on AGIOView the latest stocks trending across Twitter. Click to view dashboardSee who Agios is hiring next, click here to view […]

April 23, 2014 Bystocknews , Comments Off on Agios Pharmaceuticals Announces Pricing of Public Offering of Common Stock read more

1:52 am Agios Pharma reports initial Phase 1 data demonstrating clinical activity of AG-221, first-in-class inhibitor of IDH2 mutations, in patients with advanced blood cancers

moreView todays social media effects on AGIOView the latest stocks trending across Twitter. Click to view dashboardSee who Agios is hiring next, click here to view […]

April 8, 2014 Bystocknews , Comments Off on 1:52 am Agios Pharma reports initial Phase 1 data demonstrating clinical activity of AG-221, first-in-class inhibitor of IDH2 mutations, in patients with advanced blood cancers read more

Agios Announces Initial Phase 1 Data Demonstrating Clinical Activity of AG-221, First-in-Class Inhibitor of IDH2 Mutations, in Patients with Advanced Blood Cancers

[Business Wire] – Agios Pharmaceuticals, Inc. , a leader in the fields of cancer metabolism and inborn errors of metabolism, announced that data from its lead, first-in-class program AG-221 will be presented today at a Clinical Trials Symposium titled †moreView todays social media effects on AGIOView the latest stocks trending across Twitter. Click to view dashboardSee who Agios is […]

April 6, 2014 Bystocknews , Comments Off on Agios Announces Initial Phase 1 Data Demonstrating Clinical Activity of AG-221, First-in-Class Inhibitor of IDH2 Mutations, in Patients with Advanced Blood Cancers read more